MUTANT OF ANTIBODY VARIABLE REGION, AND USE THEREOF
The present invention provides a mutant of an antibody, and use thereof. Specifically, according to a Kabat numbering system, the mutant of the antibody has an engineered cysteine residue at any one or more positions selected from the following: positions 12, 34, 35, 38, 44, 47, 51, 60, 61, 67, 69, 78, 79, 114, or any combination thereof in a heavy chain variable region; or positions 19, 21, 44, 46, 47, 48, 62, 71, 75, 78, 87, or any combination thereof in a light chain variable region. The sulfhydryl group on the engineered cysteine can keep part of activity in the antibody expression process. The sulfhydryl group that keeps activity can be directly used for reacting with other active groups without reduction treatment. According to the cysteine-engineered antibody, the active group for drug conjugation can be obtained, which is beneficial to simplifying the production process of an antibody-drug conjugate, thereby improving the uniformity of the antibody-drug conjugate, improving the drug effect, and reducing toxic and side effects..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 04. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MA NINGNING [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-04, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
WO2024002258 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018995799 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018995799 | ||
| 003 | DE-627 | ||
| 005 | 20240209083536.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018995799 | ||
| 035 | |a (EPA)WO2024002258 | ||
| 035 | |a (EPA)89383310 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a MA NINGNING |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MUTANT OF ANTIBODY VARIABLE REGION, AND USE THEREOF |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-04, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 | ||
| 520 | |a The present invention provides a mutant of an antibody, and use thereof. Specifically, according to a Kabat numbering system, the mutant of the antibody has an engineered cysteine residue at any one or more positions selected from the following: positions 12, 34, 35, 38, 44, 47, 51, 60, 61, 67, 69, 78, 79, 114, or any combination thereof in a heavy chain variable region; or positions 19, 21, 44, 46, 47, 48, 62, 71, 75, 78, 87, or any combination thereof in a light chain variable region. The sulfhydryl group on the engineered cysteine can keep part of activity in the antibody expression process. The sulfhydryl group that keeps activity can be directly used for reacting with other active groups without reduction treatment. According to the cysteine-engineered antibody, the active group for drug conjugation can be obtained, which is beneficial to simplifying the production process of an antibody-drug conjugate, thereby improving the uniformity of the antibody-drug conjugate, improving the drug effect, and reducing toxic and side effects. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LI MINGYING |4 aut | |
| 700 | 0 | |a YU YUE |4 aut | |
| 700 | 0 | |a LIU SIXU |4 aut | |
| 700 | 0 | |a ZHANG NAN |4 aut | |
| 700 | 0 | |a LI JIAYUN |4 aut | |
| 700 | 0 | |a XU WEIWEI |4 aut | |
| 700 | 0 | |a ZHENG BOBO |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 04. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:04 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89383310/publication/WO2024002258A1?q=WO2024002258 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2024 |b 04 |c 01 |
| 951 | |a AR | ||
| 952 | |j 2024 |b 04 |c 01 | ||